Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart),
of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in
patients with exudative age-related macular degeneration and evidence of recent onset,
subfoveal and/or juxtafoveal choroidal neovascularization.